Other
Dysmenorrhea
68
Pipeline Programs↗
11
Active Trials↗
26
Companies Involved↗
Dysmenorrhea is a moderately active landscape with 68 programs across 26 companies. The most active players are PDC Biotech GmbH, FPR Specialty Pharmacy, Jiangsu Kanion Pharmaceutical Co., Ltd. 22 therapies are approved with 17 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical17
Phase 13
Phase 29
Phase 317
Analysis
Trial Status
69
clinical trials
Completed46 · 67%
Unknown status8 · 12%
Recruiting7 · 10%
Not yet recruiting4 · 6%
Terminated2 · 3%
Withdrawn2 · 3%
Clinical Trials
Trial Activity
69 trials
Posterior Tibia Nerve Neuroprolotherapy for Dysmenorrhea
Recruiting·—·Phase 1·NCT06294743·60 enrolled
IV Magnesium in the Treatment of Acute Dysmenorrhea
Recruiting·—·N/A·NCT07248540·60 enrolled
The Effectiveness of Chinese Medicine Nuan-gong-ye on Primary Dysmenorrhea
Recruiting·—·N/A·NCT06295822·82 enrolled
Effect of Virtual Reality on Prostaglandin Levels in Adolescent Females With Primary Dysmenorrhea
Not yet recruiting·—·N/A·NCT06987838·50 enrolled
Moxibustion for Primary Dysmenorrhea
Completed·—·Phase 1·NCT01972906·152 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)